SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 52.97-1.0%10:55 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Icebrg who wrote (8258)5/5/2003 9:09:23 PM
From: Ian@SI  Read Replies (2) of 52153
 
Erik,

Isn't the tradeoff:

1. Certain death without Iressa; or,
2. A 1 in 10 chance of survival with it?

... except for the several hundred unexpected deaths in Japanese pts using Iressa out of the many thousands treated.

Essentially, rather than lowering the bar perhaps the FDA is merely recognizing normal human hopes,needs or desires.

I would agree that Velcade, being almost 4 times more effective in refractory MM would seem to be a cinch for FDA approval if they'd completed their PhIII rather than just started it. All the same, I expect some form of limited approval in July at the very least.

JMO,
Ian
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News